Oncocyte Publishes Case Series Highlighting The Use Of VitaGraft Kidney Diagnostic Test To Monitor Antibody-Mediated Rejection In Kidney Transplant Patients Treated With Anti-CD38 Therapy
Portfolio Pulse from Benzinga Newsdesk
Oncocyte has published a case series demonstrating the effectiveness of its VitaGraft Kidney diagnostic test in monitoring antibody-mediated rejection in kidney transplant patients treated with anti-CD38 therapy.
August 12, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncocyte's publication of a case series on the VitaGraft Kidney diagnostic test could positively impact its stock price as it highlights the test's effectiveness in monitoring antibody-mediated rejection in kidney transplant patients treated with anti-CD38 therapy.
The publication of the case series is a significant development for Oncocyte as it showcases the potential of the VitaGraft Kidney diagnostic test. This could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100